Name: 禮來的COVID-19藥物獲得美國授權 (Eli Lilly's COVID-19 drug gets U.S. authorization)
Uploaded: 2021-02-10T20:30:26.000Z
Duration: 1 min 32 s

進階被動語態

Eli Lilly's combination antibody therapy to Fight Cove in 19 has been granted emergency use authorization in the United States.

禮來公司19年的抗科夫聯合抗體療法已在美國獲得緊急使用授權。

The company announced Tuesday It's antibody drug had been authorized by the U.

該公司週二宣佈It's antibody drug had been authorized by the U。

S Food and Drug Administration after data from a late stage try, Elin January showed it helped cut the risk of hospitalization and death in Cove in 19 patients by 70%.

S食品和藥物管理局從後期嘗試的數據後，艾林1月顯示，它有助於削減19名患者在科夫的住院和死亡風險70%。

Eli Lilly's therapy combines two antibodies Bam Lin of a map and at a seven MAB and a similar to the experimental medication touted by former US President Donald Trump after he was hospitalized with Cove in 19 last October.

禮來公司的療法結合了兩種抗體咣林的地圖和在七MAB和類似於美國前總統唐納德-特朗普在去年10月19日入院科夫後吹捧的實驗性藥物。

In a statement, the company said the therapy was authorized for the treatment of Quote mild to Moderate Cove in 19 in patients aged 12 or older who are at high risk of progressing to severe Cove in 19 and or hospitalization.

在一份聲明中，該公司表示，該療法被授權用於治療報價輕度至中度凹陷的19歲以上的12歲或以上的患者，他們有很高的風險發展到嚴重的凹陷和或住院治療。

But the FDA said the drug would not be authorized for patients who are already hospitalized to dick open 19 or require oxygen therapy.

但FDA表示，該藥物不會被授權給已經住院的患者雞巴開19或需要氧療。

Eli Lilly added that 100,000 doses would be ready immediately and an additional 150,000 doses would be available throughout the first quarter.

禮來補充說，10萬劑藥將立即準備好，另外15萬劑藥將在整個第一季度提供。

The company says they plan to manufacture upto one million doses by mid 2021 and collaboration with American biotech company Amgen.

該公司表示，他們計劃在2021年年中之前製造出多達100萬劑的產品，並與美國生物技術公司Amgen合作。

 Last November, the FDA approved Eli Lilly's single antibody treatment. 

去年11月，FDA準許了禮來的單抗治療。